FDA approve Lilly’s cluster headache treatment

FDA has announced approval of Eli Lilly’s Emgality (galcanezumab-gnlm), the first treatment for episodic cluster headache that reduces the frequency of attacks. Decision was made based on a clinical trial that compared the drug to placebo in 106 patients, and found that during a three-week period, patients taking Emgality experienced 8.7 fewer weekly cluster headache

Continue Reading